STAT+: Stealth biotech Stipple bets on secretive ADCs
Why it matters: The NIH budget cuts could impact funding for critical early-stage drug development, including ADC research.
- Stipple, a biotech company, is focusing its efforts on developing secretive Antibody-Drug Conjugates (ADCs).
- The Readout discusses the prevalent issue of 'thin science' contributing to the hype surrounding peptides within the biotech sector.
- Proposed NIH budget cuts are generating blowback and concern within the biotech and research communities.
STAT+ reports on Stipple, a stealth biotech firm making significant bets on secretive Antibody-Drug Conjugates (ADCs), a move highlighted amidst broader discussions on the often-thin scientific basis fueling peptide hype and the industry's reaction to proposed NIH budget cuts.
